actabiomedicaActa Biomedica ScientificaActa Biomedica Scientifica2541-94202587-9596Scientific Centre for Family Health and Human Reproduction Problemsactabiomedica-869Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS OF LITERATUREМОЛЕКУЛЯРНЫЕ МЕХАНИЗМЫ КАНЦЕРОГЕНЕЗА ЭНДОМЕТРИЯMOLECULAR MECHANISMS OF ENDOMETRIAL CARCINOMAГуляеваЛ. Ф.GulyaevaL. F.gulyaeva@soramn.ru,lfgulyaeva@ngs.ruКрасильниковС. Э.KrasilnikovS. E.krasilnikov@ngs.ruФГБУ Институт молекулярной биологии и биофизики СО РАМН; Новосибирский государственный университетInstitute of Molecular Biology and Biophysics, Siberian Branch of Russian Academy of Medical Sciences; Novosibirsk State UniversityНовосибирский государственный университет; Областной онкологический диспансерNovosibirsk State University; Novosibirsk Regional Oncological Hospital20122805201203(1)110115Copyright © Гуляева Л.Ф., Красильников С.Э., 20122012Гуляева Л.Ф., Красильников С.Э.Gulyaeva L.F., Krasilnikov S.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.actabiomedica.ru/jour/article/view/869

Рассмотрены молекулярно-биологические аспекты канцерогенеза эндометрия с анализом научной литературы и собственных экспериментальных данных. Показано, что в этот процесс вовлечены как классические пути сигнальной трансдукции PI3K, Wnt, Bcl-2-регулируемый апоптоз, так и гормональные пути передачи сигнала от ERα к генам-мишеням. Выявлено почти 6-кратное усиление экспрессии гена ингибитора апоптоза Bcl-2 в злокачественных опухолях эндометрия по сравнению с неопухолевой тканью. Уровень экспрессии гена ERα в половине случаев рака эндометрия был выше в опухолевой ткани по сравнению с нетрансформированной тканью. Матричные металлопротеиназы ММР-3, ММР-9, а также ген ангиогенеза Il-8 экспрессируются, главным образом, в злокачественных тканях эндометрия, но не в доброкачественных, что делает их перспективными кандидатами для характеристики опухолей матки. Таким образом, гены Bcl-2, IL8, ERα и MMPs могут быть маркерами канцерогенеза эндометрия в совокупности с такими белками PI3K- и Wnt- сигнальных путей, как PTEN и β-катенин.

Molecular aspects of carcinogenesis of endometrium with analysis of scientific literature and own experimental data are considered. It was shown that in this process are involved as well classical signal transduction pathways like PI3K, Wnt, Bcl-2-regulated apoptosis as hormonal pathways from ERα to target genes. Gene expression of apoptosis inhibitor Bcl-2 was in 6 folds higher in malignant tumors in comparison with non cancer tissue. Expression level of ERα gene was higher in cancer tissue than in adjacent non-tumor endometrium. Matrix metallo-proteinases MMR-3, MMR-9 and angiogenesis gene Il-8 expressed mainly in malignant endometrial tissues, but not in non-cancer tissues that considers these genes as suitable candidates for the characteristic of endometrial carcinoma. Thus, Bcl-2, IL8, ERα and MMPs 2 proteins can be appropriate markers of endometrial carcinoma together with the members of PI3K- and Wnt-signal pathways like PTEN and β-catenin.

рак эндометриясигнальная трансдукциямолекулярные маркерыгены апоптоза Bcl-2гены ангиогенеза IL8 и MMPsERαBAXcancer of endometriumsignal transductionmolecular markersERαapoptosis genes Bcl-2 and BAXangiogenesis genes IL8 and MMPsReferencesГуляева Л.Ф., Красильников С.Э. Молекулярно-генетические аспекты патогенеза рака эндометрия // Сибирский онкологический журнал. - 2007. - Прил. 1. - С. 55-59.Гуляева Л.Ф., Красильников С.Э. Молекулярно-генетические аспекты патогенеза рака эндометрия // Сибирский онкологический журнал. - 2007. - Прил. 1. - С. 55-59.Патогенетическое обоснование и результаты комплексной терапии рака эндометрия с использованием ингибиторов ароматазы / Н.В. Бочкарева [и др.] // Сибирский онкологический журнал. -2007. - Прил. 1. - C. 20-23.Патогенетическое обоснование и результаты комплексной терапии рака эндометрия с использованием ингибиторов ароматазы / Н.В. Бочкарева [и др.] // Сибирский онкологический журнал. -2007. - Прил. 1. - C. 20-23.Apoptosis and apoptosis-related proteins in human endometrium / T.E. Vaskivuo [et al.] // Mol. Cell. Endocrinol. - 2000. - Vol. 165. - P. 75-83.Apoptosis and apoptosis-related proteins in human endometrium / T.E. Vaskivuo [et al.] // Mol. Cell. Endocrinol. - 2000. - Vol. 165. - P. 75-83.Aromatase inhibitor letrozole in synergy with curcumin in the inhibition of xenografted endometrial carcinoma growth / Y.J. Liang [et al.] // Int. J. Gynecol. Cancer. - 2009. - Vol. 19, N 7. - P. 1248-1252.Aromatase inhibitor letrozole in synergy with curcumin in the inhibition of xenografted endometrial carcinoma growth / Y.J. Liang [et al.] // Int. J. Gynecol. Cancer. - 2009. - Vol. 19, N 7. - P. 1248-1252.Bissell M.J., Kenny P.A., Radisky D.C. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: The role of extracellular matrix and its degrading enzymes // Cold Spring Harb. Symp. Quant. Biol. - 2005. -Vol. 70. - P. 343-356.Bissell M.J., Kenny P.A., Radisky D.C. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: The role of extracellular matrix and its degrading enzymes // Cold Spring Harb. Symp. Quant. Biol. - 2005. -Vol. 70. - P. 343-356.Cantley LC. The phosphoinositide 3-kinase pathway // Science. - 2002. - Vol. 296. - P. 1655-1657.Cantley LC. The phosphoinositide 3-kinase pathway // Science. - 2002. - Vol. 296. - P. 1655-1657.Carey L.A. Directed therapy of subtypes of triple-negative breast cancer // Oncologist. - 2010. -Vol. 5. - P. 59-46.Carey L.A. Directed therapy of subtypes of triple-negative breast cancer // Oncologist. - 2010. -Vol. 5. - P. 59-46.Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer // J. Clin. Oncol. - 2010. - Vol. 28. - P. 1075-1083.Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer // J. Clin. Oncol. - 2010. - Vol. 28. - P. 1075-1083.Dobrzycka B., Terlikowski S. J., Garbowicz M. The prognostic significance of the immunohistochemical expression of P53 and BCL-2 in endometrial cancer // Folia Histochem. Cytobiol. - 2011. - Vol. 49, N 4. -P. 631 -635.Dobrzycka B., Terlikowski S. J., Garbowicz M. The prognostic significance of the immunohistochemical expression of P53 and BCL-2 in endometrial cancer // Folia Histochem. Cytobiol. - 2011. - Vol. 49, N 4. -P. 631 -635.Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus / P. Cardona-Gomez [et al.] // Mol Cell Neurosci. - 2004. - Vol. 25. - P. 363-373.Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus / P. Cardona-Gomez [et al.] // Mol Cell Neurosci. - 2004. - Vol. 25. - P. 363-373.Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium / A.G. Braundmeier [et al.] // J. Clin. Endocrinol. Metabolism. - 2006. - Vol. 91. -P. 2358-2365.Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium / A.G. Braundmeier [et al.] // J. Clin. Endocrinol. Metabolism. - 2006. - Vol. 91. -P. 2358-2365.Folkman J. Fundamental concepts of angiogenic process // Current mol. med. - 2003. -Vol. 3. - P. 643- 651.Folkman J. Fundamental concepts of angiogenic process // Current mol. med. - 2003. -Vol. 3. - P. 643- 651.Foxa E.M., Andradeb J., Shupnik M.A. Novel actions of estrogen to promote proliferation: Integration of cytoplasmic and nuclear pathways // Steroids. - 2009. - Vol. 74. - P. 622-627.Foxa E.M., Andradeb J., Shupnik M.A. Novel actions of estrogen to promote proliferation: Integration of cytoplasmic and nuclear pathways // Steroids. - 2009. - Vol. 74. - P. 622-627.Georgescu M.-M. PTEN tumor suppressor network in PI3K-Akt pathway control // Genes & Cancer. - 2011. - Vol. 1, N 12. - P. 1170-1177.Georgescu M.-M. PTEN tumor suppressor network in PI3K-Akt pathway control // Genes & Cancer. - 2011. - Vol. 1, N 12. - P. 1170-1177.Horowitz N., Matulonis U.A. New biologic agents for the treatment of gynecologic cancers // Hematol. / oncol. clinics North America. - 2012. -Vol. 26, N 1. - P. 133-156.Horowitz N., Matulonis U.A. New biologic agents for the treatment of gynecologic cancers // Hematol. / oncol. clinics North America. - 2012. -Vol. 26, N 1. - P. 133-156.Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases // Cell. - 2010. -Vol. 141. - P. 1117-1134.Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases // Cell. - 2010. -Vol. 141. - P. 1117-1134.Mannelqvist M., Stefansson I.M., Bredholt G. Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer // Am. J. pathol. - 2011. - Vol. 178, N 2. - P. 861 - 871.Mannelqvist M., Stefansson I.M., Bredholt G. Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer // Am. J. pathol. - 2011. - Vol. 178, N 2. - P. 861 - 871.Marino M., Galluzzo P., Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription // Curr. Genomics. - 2006. - Vol. 7, N 8. -P. 497-508.Marino M., Galluzzo P., Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription // Curr. Genomics. - 2006. - Vol. 7, N 8. -P. 497-508.Mutter G.L., Lin M.C., Fitzgerald J.T. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers // J. Natl. Cancer Inst. -2000. - Vol. 92. - P. 924-930.Mutter G.L., Lin M.C., Fitzgerald J.T. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers // J. Natl. Cancer Inst. -2000. - Vol. 92. - P. 924-930.Novel molecular profiles of endometrial cancer - new light through old windows / A. Doll [et al.] // J. Steroid Biochem. & Mol. Biol. - 2008. -Vol. 108. - P. 221-229.Novel molecular profiles of endometrial cancer - new light through old windows / A. Doll [et al.] // J. Steroid Biochem. & Mol. Biol. - 2008. -Vol. 108. - P. 221-229.Purohita A., Woob L.W. L., Potterb B.V.L. Steroid sulfatase: A pivotal player in estrogen synthesis and metabolism // Mol. Cell. Endocrinol. - 2011. -Vol. 340. - P.154-160.Purohita A., Woob L.W. L., Potterb B.V.L. Steroid sulfatase: A pivotal player in estrogen synthesis and metabolism // Mol. Cell. Endocrinol. - 2011. -Vol. 340. - P.154-160.Rauh-Hain J.A., Del Carmen M.G. Treatment for advanced and recurrent endometrial carcinoma: combined modalities // Oncologist. - 2010. -Vol. 15. - P. 852-861.Rauh-Hain J.A., Del Carmen M.G. Treatment for advanced and recurrent endometrial carcinoma: combined modalities // Oncologist. - 2010. -Vol. 15. - P. 852-861.Thomas C., Gustafsson J.A. The different roles of ER subtypes in cancer biology and therapy // Nat. Rev. Cancer. - 2011. - Vol. 11, N 8. - P. 579-608.Thomas C., Gustafsson J.A. The different roles of ER subtypes in cancer biology and therapy // Nat. Rev. Cancer. - 2011. - Vol. 11, N 8. - P. 579-608.Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry // Circ. Res. - 2003. -Vol. 92. - P. 827-839.Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry // Circ. Res. - 2003. -Vol. 92. - P. 827-839.Wang Y., Hanifi-Moghaddam P., Hanekamp E.E. Progesterone inhibition of Wnt/betacatenin signaling in normal endometrium and endometrial cancer // Clin Cancer Res. - 2009. - Vol. 15. -P. 5784-5793.Wang Y., Hanifi-Moghaddam P., Hanekamp E.E. Progesterone inhibition of Wnt/betacatenin signaling in normal endometrium and endometrial cancer // Clin Cancer Res. - 2009. - Vol. 15. -P. 5784-5793.Wnt/B-catenin and sex hormone signaling in endometrial homeostasis and cancer / Y. Wang [et al.] // Oncotarget. - 2010. - Vol. 1, N 7. -P. 674-684.Wnt/B-catenin and sex hormone signaling in endometrial homeostasis and cancer / Y. Wang [et al.] // Oncotarget. - 2010. - Vol. 1, N 7. -P. 674-684.Zhang S., Yu D. PI(3)king apart PTEN's role in cancer // Clin Cancer Res. - 2010. - Vol. 16. -P. 4325-4330.Zhang S., Yu D. PI(3)king apart PTEN's role in cancer // Clin Cancer Res. - 2010. - Vol. 16. -P. 4325-4330.

The authors declare that there are no conflicts of interest present.